AsianScientist (Mar. 12, 2014) – Biostar Pharmaceuticals Inc., a China-based manufacturer of pharmaceutical and health supplement products, has signed a letter of intent with the Research Institute of Pharmaceuticals at Shaanxi University of Chinese Medicine to develop a new liver cancer drug based on an oleanolic acid injection.
In recent years, new cancer cases and fatalities have increased sharply around the world, with China bearing the heaviest toll of this increase. According to the World Health Organization (WHO), there were 14 million new cancer cases and 8.2 million deaths around the world in 2012, with China accounting for 21.8% of the new cancer cases, and 26.9% of the deaths. China’s own estimates for the same periods are slightly higher than the WHO figures.
Liver, lung, esophageal and stomach cancers are the most common cancers for the Chinese population. In 2012, about 50% of global liver cancer cases and 51% of worldwide deaths caused by liver cancer were recorded in China. One of the major causes for such alarming statistics is that China has more than 40 million hepatitis B patients. Many of these hepatitis B patients do not receive timely and proper care, leading to the development of liver cancer, among other conditions.
“We are very glad to team up with Shaanxi University of Chinese Medicine to jointly develop oleanolic acid injection drug for liver cancer after numerous rounds of market research and in-depth discussion with many research institutions in China,” said Mr. Ronghua Wang, Chairman & CEO of Biostar Pharmaceuticals, Inc.
——
Source: Biostar Pharmaceuticals.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
